Wheeler Bio announced today that it expanded its capabilities through the licensing of ATUM’s miFuc platform. ATUM designed miFuc for the expression of recombinant proteins containing afucosylated glycans. The technology supports the development of antibodies with a significant reduction in fucosylation without affecting product titer, cellular growth rates or incurring global glycan liabilities. ATUM’s proprietary…
Wheeler Bio closes $31M Series A financing round to strengthen its alternative CDMO model
The boutique contract development and manufacturing organization (CDMO) Wheeler Bio has closed a $31 million Series A financing round, which it plans to use to complete a CGMP cell banking and drug substance manufacturing facility in Oklahoma City. The company specializes in process development and small batch CGMP production of therapeutic antibodies. Wheeler says the…